Last reviewed · How we verify
NCT04887298
Study of Liposomal Annamycin for the Treatment of Subjects with Soft-Tissue Sarcomas (STS) with Pulmonary Metastases
Phase 1, PHASE2 trial testing Liposomal Annamycin (L-Annamycin) in Sarcoma,Soft Tissue in 36 participants. Completed in 6 August 2024.
29 September 2022
Quick facts
| Lead sponsor | Moleculin Biotech, Inc. |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 36 |
| Start date | 5 June 2021 |
| Primary completion | 29 September 2022 |
| Estimated completion | 6 August 2024 |
| Sites | 5 locations across United States |
Drugs / interventions tested
- Liposomal Annamycin (L-Annamycin) — full drug profile →
Conditions studied
- Sarcoma,Soft Tissue — all drugs for Sarcoma,Soft Tissue →
- Pulmonary Metastasis — all drugs for Pulmonary Metastasis →
Sponsor
Moleculin Biotech, Inc. — full company profile →
Who can join
18 and older, any sex, with Sarcoma,Soft Tissue or Pulmonary Metastasis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a multi-center, open-label, single-arm study that in Phase 1b will determine the maximum tolerated dose (MTD)/ recommended phase 2 dose (RP2D) and safety of L-Annamycin and in Phase 2 will explore the efficacy of L- Annamycin as a single agent for the treatment of subjects with STS with lung metastases for which chemotherapy is considered appropriate.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Nanoparticles in the clinic: An update post COVID-19 vaccines.
Anselmo AC, Mitragotri S. · · 2021 · cited 211× · PMID 34514159 · DOI 10.1002/btm2.10246
Verify or expand the search:
- PubMed search for NCT04887298
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Sarcoma,Soft Tissue
Currently open trials in the same condition.
- NCT06835049 — Feasibility of Total Neoadjuvant Treatment With HYPErthermia in Patients With High-risk Extremity and Trunk Soft Tissue · Phase 2 · recruiting
- NCT07066982 — Sequential Infusion of CD146-Targeted and HER2-Targeted CAR T Cells in Patients With Advanced Sarcomas · Phase 1, PHASE2 · recruiting
- NCT06660810 — Neoadjuvant Intralesional Injection of Talimogene Laherparepvec · Phase 2 · active not recruiting
- NCT06637007 — Phase II Clinical Trial of Chidamide Combined With AK112 for Second-line and Advanced Bone and Soft Tissue Sarcoma · Phase 2 · recruiting
- NCT05813327 — Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma · Phase 1 · active not recruiting
Other Moleculin Biotech, Inc. trials
Trials by the same sponsor.
- NCT05319587 — Study of Liposomal Annamycin in Combination With Cytarabine for the Treatment of Subjects With Acute Myeloid Leukemia (A · Phase 1, PHASE2 · completed
- NCT05195723 — Study to Assess the Safety and Pharmacokinetics of WP1122 in Healthy Volunteers · Phase 1 · completed
- NCT04702503 — Study of WP1220 for the Treatment of Adult Subjects With Cutaneous T-Cell Lymphoma (CTCL) · Phase 1 · completed
- NCT03388749 — Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML) · Phase 1, PHASE2 · completed
- NCT03315039 — Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML) · Phase 1, PHASE2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04887298 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Moleculin Biotech, Inc.
- Last refreshed: 24 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04887298.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing